ArticleAnnals of nuclear medicine2021
Therapeutic efficacy of
Article in Annals of nuclear medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 5 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Beyond [BMC cancer · 2026Pooled it
- Evaluating Xerostomia as a side effect of [European journal of nuclear medicine and molecular imaging · 2025Pooled it
- Pooled it
- Time for action: actinium-225 PSMA-targeted alpha therapy for metastatic prostate cancer - a systematic review and meta-analysis.Theranostics · 2025Pooled it
- Efficacy and Safety ofFrontiers in oncology · 2022Pooled it
- Evaluation of [The Prostate · 2026Observational
- Clinical perspective on targeted alpha therapy usingAnnals of nuclear medicine · 2025Review
- Radiotheranostics in Low- and Middle-Income Countries: Challenges, Practice, and Prospects.World journal of nuclear medicine · 2025Review
- Targeted Alpha Therapy: Exploring the Clinical Insights into [225Ac]Ac-PSMA and Its Relevance Compared with [177Lu]Lu-PSMA in Advanced Prostate Cancer Management.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Advances in PSMA-Targeted Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer.Cancer management and research · 2025Review
- The efficacy and safety ofFrontiers in oncology · 2025Article
- Design ofAnnals of translational medicine · 2024Review
- A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Targeted Alpha Therapy: All We Need to Know aboutPharmaceuticals (Basel, Switzerland) · 2023Review
- Article
- Review
- The current status of prostate cancer treatment and PSMA theranostics.Therapeutic advances in medical oncology · 2023Review
- Prostate specific membrane antigen binding radiopharmaceuticals: Current data and new concepts.Frontiers in medicine · 2022Review
- Targeted thorium-227 conjugates as treatment options in oncology.Frontiers in medicine · 2022Review
- PSMA Theranostics: Science and Practice.Cancers · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesMATERIALS AND
methodsThirty-eight patients with CRPC with progressive disease following at least one taxane-based chemotherapy received
resultsA composite response by predetermined criteria was observed in 25 (66%) of 38 patients. The median PFS was 8 months (95% CI 5.3-10.6 months). Median overall survival was 12 months (95% CI 9.1-14.9) with 16 patients alive at the time of censorship. There was no difference in response rates or survival statistics between patients with visceral metastases versus those with only bone and lymph-node metastases (Chi-square 1.51, df 1, Sig 0.218). The most common adverse effect was xerostomia. On the QOL Symptom score, Pain, Fatigue Insomnia, and constipation showed a significant improvement as compared to baseline.
conclusions
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.